Arbor, Lupin End IP Suit Over Planned Blood Pressure Generic

By Lauren Berg (April 19, 2022, 8:34 PM EDT) -- A Delaware federal judge has signed off on the joint dismissal of a patent infringement suit brought by Arbor Pharmaceuticals and Takeda Pharmaceutical Co., the makers of blood pressure drug Edarbi, over Lupin Pharmaceuticals' planned generic.

On Monday, just a month before the scheduled trial, U.S. District Judge Maryellen Noreika signed the stipulation and order of dismissal without prejudice of Arbor and Takeda's suit against Lupin.

"Plaintiffs Arbor Pharmaceuticals LLC and Takeda Pharmaceutical Co. Ltd., and defendants Lupin Ltd. and Lupin Pharmaceuticals Inc., hereby stipulate that the above-captioned action, including all claims, counterclaims and defenses, are hereby dismissed in their entirety...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!